Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Paclitaxel Stent Restenosis Rate Is Zero At Six Months

This article was originally published in The Gray Sheet

Executive Summary

Results of a 61-patient, three-center German study of Boston Scientific's paclitaxel-coated NIRx coronary stent appear to match the high standards established in recently released drug-coated stent studies sponsored by Johnson & Johnson/Cordis and Cook.

You may also be interested in...



Boston Scientific, Medinol Coronary Stent IDE Approvals Precede Legal Duel

Medinol's April 2001 lawsuit alleging Boston Scientific's development of the Express stent constitutes a breach of contract will likely be heard in New York federal court by late summer

Boston Scientific, Medinol Coronary Stent IDE Approvals Precede Legal Duel

Medinol's April 2001 lawsuit alleging Boston Scientific's development of the Express stent constitutes a breach of contract will likely be heard in New York federal court by late summer

Drug-Coated Stent Pivotal Study Will Show Improved TVR Rates, Cook Says

Cook's 1,200-patient, six-center U.S. pivotal trial (PATENCY) evaluating the Logic PTX paclitaxel-coated stent in treating de novo lesions should complete enrollment in early 2002.

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel